Sunlight review

What it is

A telehealth platform whose core business is compounded GLP-1 weight loss, with compounded NAD⁺ and sermorelin as a newer secondary line built on the same funnel. NAD⁺ ships as a ready-to-use liquid subcutaneous injection; sermorelin ships as a lyophilised powder with bacteriostatic water for reconstitution. There is no testosterone product — the site's entire page sitemap is its homepage, two landers, a GLP-1 page and legal pages — which is why it does not appear on our TRT board. Coverage is every US state except Mississippi, with a waitlist offered otherwise.

How it works

Asynchronous-first with a conditional synchronous step, which the site explains honestly: appointments are required only in certain situations, such as when your medical history needs further review or the medication requires closer monitoring, and not all patients will need to meet a provider. A virtual visit, when triggered, is booked after intake and checkout. Labs are mandatory but deferred — all patients must complete testing before their third prescription is issued, and some intakes require them sooner. Pricing is fully public before signup. Supply is a monthly four-week shipment with injection supplies included and cancellation available from the patient dashboard. The disclosure here is the reason to take Sunlight seriously: it names six compounding pharmacies with their phone numbers, and names its medical group and two physicians with NPI numbers — a level of supply-chain transparency nothing else in this batch approaches. Two open questions remain. Labs are required by the third fill but the site never says who pays for the draw, while answering "no" to whether any cost exists beyond the subscription. And its membership language contradicts itself: every call-to-action badge reads "No Monthly Membership" while the NAD⁺ FAQ refers to cancelling your "membership" and the help centre asks about costs beyond the "monthly subscription".

Pricing transparency

Simple and, unusually for this batch, honestly simple. Both sermorelin and NAD⁺ are listed at $159 a month, stated as a monthly cost in a pricing table on two independent pages, with no commitment tier, no prepayment ladder and no membership fee underneath. That is a genuine floor and both cards carry it. The GLP-1 side of the business runs promotional rates of $88 for compounded semaglutide and $157 for tirzepatide, described as flat monthly rates including prescription, unlimited telehealth visits and shipping. One thing not published: any per-dose or per-vial breakdown, the cost of the mandatory lab draw, or a bundled rate if you take sermorelin and NAD⁺ together — both are listed at the identical $159 with no differentiation between them, which is itself a small signal that the price is a house rate rather than a molecule-specific one.

Branded vs compounded

Compounded; not FDA-approved — and Sunlight states this correctly and prominently on its peptide lander and repeats it verbatim in every peptide help-centre article, alongside a genuinely useful warning steering readers away from grey-market "research peptides". Its product documentation is deep: fifteen articles covering ingredients, reconstitution, dosing, storage, sourcing and side effects, with the sermorelin formulation's inactive ingredient named. Three faults sit on the NAD⁺ page specifically and they are worth knowing before you read it. It calls the product "a single daily peptide" — NAD⁺ is a dinucleotide coenzyme, not a peptide, which is simply the wrong molecular class. It carries a dietary-supplement FDA disclaimer, the "these statements have not been evaluated by the Food and Drug Administration" formula, on a page selling a prescription compounded drug — contradicting the correct compounded disclaimer the same company uses on its other lander. And its medical-oversight paragraph states that treatment is "provided through Direct Meds", a different company, on the one paragraph whose job is to establish who is responsible for your care. Its reference list also cites a resveratrol paper dated 1996, a year that literature does not have. On the evidence: injected NAD⁺ has no controlled human outcome trials, and the page's claims of roughly 100% bioavailability and results felt within days carry no citation. Sermorelin is positioned more defensibly, as an adjunct during rapid GLP-1 weight loss with the goal of supporting muscle retention. Individual results vary.

Pros and watch-outs

The evidence behind what Sunlight prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD injections: how to get them near you or online, and what the evidence really says

  Subcutaneous NAD+ injections are sold as a cheaper, at-home alternative to the IV drip — via “near me” clinics or telehealth shipped to your door. They’re compounded, not FDA-approved, and have no outcome trials; oral NR/NMN precursors are the route with the human data.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

How Sunlight compares

A few alternatives worth a look, depending on what you’re optimizing for.

• OLOak Longevity

  Low-cost sermorelin within a broader longevity stack

  See Oak Longevity →
• HEHealthRX

  Compounded sermorelin within a broad longevity and weight-care menu

  See HealthRX →
• BHBodybuilding Health+

  Pairing sermorelin with a strength-training and recovery focus

  See Bodybuilding Health+ →